Palvella Therapeutics公司宣布,其用于治疗皮肤静脉畸形的Qtorin™ Rapamycin在II期Toiva临床试验中取得的最新数据,已于第83届皮肤病研究学会年会上公布。
Palvella Therapeutics公司宣布,其用于治疗皮肤静脉畸形的Qtorin™ Rapamycin在II期Toiva临床试验中取得的最新数据,已于第83届皮肤病研究学会年会上公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.